Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07243249 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study Evaluating the Impact of Using Triplex Rapid Diagnostic Tests (SARS-CoV-2/Influenza/RSV) on Antibiotic Prescribing

Study acronym: TROD-VILLE
StatusRecruiting
PhaseNot applicable
Started2026-01-07
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 14 months later Apr 2026 → Jul 2027
See other at-risk trials from Assistance Publique - Hôpitaux de Paris

Amendment history

2026-09-04
critical
Study Status v2
Primary completion pushed: 2026-04 → 2027-07
Completion pushed: 2026-04 → 2027-07
2026-01-13
notable
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2025-11→confirmed 2026-01-07
Study sites0→1
2025-11-17
minor
Original filing
Respiratory infections are very common, especially during winter, and are often caused by viruses such as influenza, SARS-CoV-2 or respiratory syncytial virus (RSV). These illnesses are generally mild, but their symptoms do not always allow a clear distinction to be made between a viral infection and a bacterial infection. In the absence of a precise diagnosis, antibiotics may be prescribed when they are not necessary in many cases. However, the excessive use of antibiotics contributes to the development of bacterial resistance, which is a major public health issue. The aim of this study is to better understand whether the use of a rapid test (called TROD), which can quickly identify certain respiratory viruses, can help doctors reduce unnecessary antibiotic prescriptions for these infections. The test will be performed using a swab gently inserted into the nose.
Trial Details
NCT Number NCT07243249
Lead Sponsor Assistance Publique - Hôpitaux de Paris
Conditions Respiratory Infections, Antibiotic
Enrollment 2,000 participants
Start Date 2026-01-07
Primary Completion 2027-07 (estimated)
Study Completion 2027-07 (estimated)
Updated on ClinicalTrials.gov 2026-09-08